Jump to content

PubMed RSS Feed - - Anti-inflamatory dose doxycycline in the treatment of rosacea.


rss

Recommended Posts

Anti-inflamatory dose doxycycline in the treatment of rosacea.

J Drugs Dermatol. 2009 Jul;8(7):664-8

Authors: Del Rosso JQ

Anti-inflammatory dose doxycycline (ADD), which is the administration of doxycycline 40 mg extended-release capsule once daily, is the only oral therapy approved by the United States Food and Drug Administration (FDA) for treatment of rosacea. ADD once daily has been shown to exhibit anti-inflammatory activity while not demonstrating evidence of antibiotic effects, including with chronic administration. This article summarizes the clinical studies to date on the use of ADD once daily in papulopustular rosacea, including both monotherapy and combination therapy studies. The combination therapy approach of ADD once daily and metronidazole gel 1% once daily has been shown to exhibit a more rapid onset of therapeutic effect than topical therapy alone. ADD once daily has been demonstrated to be effective in adult subjects with moderate to severe rosacea, and exhibits a favorable safety profile coupled with absence of antibiotic selection pressure. Additionally, a much lower incidence of gastrointestinal side effects has been noted with ADD once daily as compared to doxycycline 100 mg once daily.

PMID: 19588643 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...